Synedica Tirzepatide 40mg

Synedica Tirzepatide 40mg is a tirzepatide-based product formulated around the dual GIP and GLP-1 receptor agonist compound. Tirzepatide has become one of the most extensively studied incretin-based compounds, with research focusing on glucose metabolism, appetite signaling, body-weight regulation, and metabolic health.

The Synedica Tirzepatide 40mg Injection Pen Kit is listed as a 40mg pen kit containing one pen, 12 disposable needles, and an instruction booklet. Synedica also publishes product and batch-testing information for its formulation.

What Is Synedica Tirzepatide 40mg?

Synedica Tirzepatide 40mg contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Tirzepatide works through two incretin pathways rather than targeting GLP-1 alone, which has made it an important compound in metabolic and endocrinology research.

Research involving tirzepatide includes:

• GIP receptor activity
• GLP-1 receptor activity
• Glucose metabolism
• Insulin signaling
• Glucagon regulation
• Appetite and satiety pathways
• Body-weight regulation
• Metabolic health research
• Incretin pharmacology

Tirzepatide is the active pharmaceutical ingredient in Mounjaro and Zepbound. The FDA approved Mounjaro in 2022 for improving blood-glucose control in adults with type 2 diabetes, and approved Zepbound in 2023 for chronic weight management in eligible adults.

Synedica Tirzepatide 40mg Injection Pen Kit

The Synedica listing identifies the product as a Tirzepatide 40mg Injection Pen Kit.

The listed kit contains:

• 1 × Tirzepatide 40mg pen
• 12 × disposable needles
• 1 × instruction booklet

Synedica’s product information also publishes analytical testing data for the listed batch, including HPLC identification, purity, peptide content, assay, endotoxin and other quality specifications.

Tirzepatide GIP and GLP-1 Dual Agonist

Tirzepatide is different from traditional GLP-1-only compounds because it activates both GIP and GLP-1 receptors.

These two incretin pathways are involved in important metabolic processes, including insulin secretion, glucose regulation and appetite-related signaling. The dual-agonist mechanism is a major reason tirzepatide has attracted significant scientific and clinical interest.

The FDA describes tirzepatide as a GIP and GLP-1 receptor agonist.

Synedica Tirzepatide 40mg Research Applications

Tirzepatide research can involve several areas of metabolic science and pharmacology.

Metabolic Research

Researchers study tirzepatide in relation to glucose metabolism, insulin signaling, energy balance and other metabolic pathways.

GIP and GLP-1 Research

The dual-receptor mechanism makes tirzepatide useful for investigating interactions between GIP and GLP-1 signaling.

Appetite Research

Research has examined incretin pathways involved in appetite, satiety and food-intake regulation.

Body-Weight Research

Tirzepatide has been extensively studied in clinical research involving body weight and metabolic outcomes.

Pharmacology Research

Researchers can investigate receptor activity, pharmacokinetics, formulation characteristics and other properties associated with tirzepatide.

Synedica Tirzepatide 40mg Quality Information

For research products, documentation and independent analytical testing are important when evaluating product quality.

Synedica publishes batch information for its Tirzepatide 40mg formulation. Its listed testing includes:

• HPLC identification
• HPLC purity
• Peptide content
• Assay
• pH
• Water content
• Endotoxin testing
• Sterility
• GIP/GLP-1 activity

The published batch record reports passing results against the specifications shown on the Synedica product page.

Researchers should review the applicable certificate of analysis, batch number, storage requirements, documentation and local regulatory requirements before working with any research compound.

Synedica Tirzepatide 40mg Product Specifications

Product: Synedica Tirzepatide 40mg
Compound: Tirzepatide
Total amount: 40mg
Product format: Injection pen kit
Receptor activity: GIP and GLP-1
Kit: 1 pen, 12 disposable needles and instruction booklet
Research areas: Metabolic, incretin and pharmacology research

Synedica’s current product catalogue also lists Tirzepatide 40mg alongside its other injection pen formulations.

Important Tirzepatide Notice

Tirzepatide is an approved prescription medicine in specific FDA-approved products and indications. However, the existence of FDA-approved tirzepatide medicines does not mean every tirzepatide product or formulation on the market has FDA approval.

This page describes Synedica Tirzepatide 40mg for informational and research purposes. It should not be interpreted as medical advice, a treatment recommendation, or a substitute for consultation with a qualified healthcare professional.

Synedica Tirzepatide 40mg — Key Information

Synedica Tirzepatide 40mg is a 40mg tirzepatide formulation associated with dual GIP and GLP-1 receptor activity. The Synedica listing identifies it as an injection pen kit containing one 40mg pen, 12 disposable needles and an instruction booklet.

With strong topical relevance around Synedica Tirzepatide 40mg, Tirzepatide 40mg, Tirzepatide injection pen, Tirzepatide pen kit, GIP GLP-1 agonist, and Tirzepatide research, this page is structured to target both the primary product search and closely related informational queries.